Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 10 mg in Korean Adults With Type 2 Diabetes: A Multicentre, Randomised, Double‐Blind, Placebo‐Controlled Phase III Trial
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: AIMS: To evaluate the efficacy and safety of anagliptin added to metformin and empagliflozin 10 mg in adults with Type 2 diabetes (T2D) with inadequate glycaemic control. MATERIALS AND METHODS: In this multicentre, randomised, double-blind, placebo-controlled Phase III trial, participants receiving metformin (≥ 1000 mg/day) plus empagliflozin 10 mg/day were randomised 1:1 to anagliptin 100 mg twice daily or placebo for 24 weeks. The primary endpoint was change in glycated haemoglobin (HbA1c) at Week 24 in the full analysis set, analysed using a mixed-effects model for repeated measures. Secondary endpoints included fasting plasma glucose (FPG), HbA1c target attainment, HOMA-β and safety. Glycaemic responder analyses were conducted post hoc. RESULTS: The full analysis set included 195 participants (anagliptin, n = 97; placebo, n = 98). At Week 24, LS mean HbA1c changes were -0.81% and -0.24%, respectively, yielding a treatment difference of -0.57% (95% CI -0.74 to -0.40; p < 0.0001). FPG was also significantly reduced (between-group difference -12.15 mg/dL, 95% CI -19.18 to -5.12; p = 0.0008). HbA1c ≤ 7.0% was achieved by 55.7% versus 25.5% of participants. HbA1c reductions ≥ 0.5% occurred in 68.0% versus 27.6%, and reductions ≥ 1.0% in 33.0% versus 9.2%. HOMA-β improved significantly with anagliptin (between-group difference 14.35, 95% CI 7.37-21.32; p < 0.0001). Treatment-emergent adverse events occurred in 22.7% and 17.2%, respectively; no hypoglycaemic events or deaths were reported. CONCLUSIONS: Anagliptin added to metformin and empagliflozin 10 mg provided confirmatory evidence of additional glycaemic efficacy in a separately randomised Korean population, increased glycaemic responder rates and improved estimated β-cell function, with acceptable short-term tolerability. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05814406.
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.71501
Institutions: Eulji University, Daejeon Eulji Medical Center, Eulji University, Chosun University Hospital, JW Pharmaceutical (South Korea), Keimyung University Dongsan Medical Center, Keimyung University Daegu Dongsan Hospital, Keimyung University Dongsan Hospital, Keimyung University, Eulji University Nowon Eulji Medical Center, Ajou University, University of Ulsan, Ulsan University Hospital, Eulji University Uijeongbu Eulji Medical Center
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7234247945
